Mirabegron Teva

Mirabegron, the active ingredient in Mirabegron Teva, is a β3‑adrenergic receptor agonist presented as an oral tablet for oral use. It is indicated for the treatment of overactive bladder symptoms such as urinary urgency, frequency and urge incontinence in adult patients.

GNH USA supplies Mirabegron Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets EU regulatory standards and is manufactured under strict quality controls.

Mirabegron is used to manage conditions related to overactive bladder and associated urinary symptoms. - Overactive bladder: improves bladder capacity and reduces urgency episodes. - Urinary urgency: decreases the frequency of sudden urges to void. - Urinary frequency: lowers the number of daytime voids. - Urge urinary incontinence: reduces involuntary leakage episodes.

Adverse reactions reported with mirabegron vary in frequency and severity.

Common Side Effects: - Hypertension: increase in blood pressure. - Headache: mild to moderate intensity. - Nasopharyngitis: upper respiratory tract infection symptoms. - Constipation: reduced bowel movements. - Dry mouth: decreased salivation. - Urinary retention: difficulty emptying the bladder.

Serious or Rare Side Effects: - Severe hypertension: markedly elevated blood pressure requiring medical attention. - Angioedema: swelling of face, lips or airway. - Cardiac arrhythmia: irregular heart rhythm. - Acute urinary retention: sudden inability to void. - Myocardial infarction: rare heart attack events.

Before initiating mirabegron therapy, several safety considerations should be evaluated. - Blood pressure assessment: measure baseline and monitor regularly. - Urinary retention monitoring: watch for signs of incomplete bladder emptying. - Renal function review: adjust use in patients with severe impairment. - Hepatic impairment caution: use with care in moderate to severe liver disease. - Concomitant antihypertensive therapy: observe for additive blood pressure effects. - Store at ambient temperature: keep in original container, protect from moisture and light.

Mirabegron can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): may increase mirabegron exposure. - Anticholinergic agents: combined use can heighten risk of urinary retention. - Monoamine oxidase inhibitors: potential for hypertensive reactions.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may modestly raise mirabegron levels. - CYP3A4 inducers (e.g., rifampin): may reduce mirabegron efficacy. - Antihypertensive drugs: additive blood pressure‑lowering effect. - Diuretics: may increase risk of dehydration and hypotension.